Work

Effect of Switching from Glucagon-like Peptide-1 Receptor Agonists to Tirzepatide in Patients with Type 2 Diabetes: A Retrospective Observational Study

Year: 2026

Type: article

Abstract: Aims: This study was designed to investigate the effect of switching from glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) to weekly subcutaneous tirzepatide on glycemic control, as reflected by hemoglobin A1c (HbA1c), occasional plasma glucose (PG) and glycoalbumin (GA), in real-world clinical practice in our hospital. Patients and Methods: A search of electronic medical records from June 2024 to July 2025 was performed for patients who had received GLP-1RAs for type 2 diabetes and were switched to tirzepatide mainly because of poor glycemic control. A total of 21 patients were enrolled and data for these patients were evaluated until the end of January 2026. Results: Tirzepatide was not suspended in any cases during the observational period of 6 months after the switch. After the change to tirzepatide, HbA1c significantly decreased from baseline at 3 and 6 months. Occasional PG showed a significant decrease from baseline at 6 months, and GA significantly decreased from baseline at 3 and 6 months. There were no significant differences in low-density lipoprotein cholesterol, aspartate transaminase, alanine transaminase, gamma-glutamyl transpeptidase, uric acid, or estimated glomerular filtration rate at all time points. There was a significant decrease of body weight (BW) from baseline at 6 months, and a significant correlation of BW change with the change of HbA1c from baseline to 6 months. Baseline body mass index showed a significant positive correlation with the HbA1c change from baseline to 3 months. Conclusion: The switch from GLP-1RAs to tirzepatide significantly improved glycemic control evaluated by HbA1c, occasional PG and GA over a 6-month observational period. Tirzepatide also significantly decreased BW.

Source: Institutional Repositories DataBase (IRDB)